AstraZeneca urged to avoid $400bn US mega-merger, stick with strategy
A Guardian analysis argues AstraZeneca does not need a $400bn US mega-merger to succeed, urging the company to stay with its current winning formula. The piece suggests pursuing such a deal could introduce risk and distraction, despite pressure for scale in the pharma sector.